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Review of the existing literature suggests that consumption of soy foods or an exposure to a soy isoflavone genistein during
childhood and adolescence in women, and before puberty onset in animals, reduces later mammary cancer risk. In animal studies, an
exposure that is limited to the fetal period or adult life does not appear to have the same protective effect. A meta-analysis of human
studies indicates a modest reduction in pre- and postmenopausal risk when dietary intakes are assessed during adult life. These
findings concur with emerging evidence indicating that timing may be vitally important in determining the effects of various dietary
exposures on the susceptibility to develop breast cancer. In this review, we address the mechanisms that might mediate the effects of
an early life exposure to genistein on the mammary gland. The focus is on changes in gene expression, such as those involving BRCA1
and PTEN. It will be debated whether mammary stem cells are the targets of genistein-induced alterations and also whether the
alterations are epigenetic. We propose that the effects on mammary gland morphology and signalling pathways induced by pubertal
exposure to genistein mimic those induced by the oestrogenic environment of early first pregnancy.
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GENISTEIN AND BREAST CANCER
The assumption that high soy intake among Asian women explains
their low breast cancer risk has led to numerous studies carried out
in human populations and animal models. Human studies suggest
that there indeed is a modest inverse association between high soy
food consumption and reduced risk (Trock et al, 2006; Wu et al,
2008). However, several questions remain regarding a causative
role of soy consumption in reducing breast cancer risk; the
possibility that the association simply reflects other factors/
‘healthy’ lifestyle affecting breast cancer risk cannot be excluded
at the present time.
Many animal studies do not support an association between an
exposure to this phytochemical during adulthood and reduced
mammary tumorigenesis (Tables 1 and 2). The protective role of
soy intake during adulthood is further questioned by the results
obtained in an intervention study on premenopausal women
showing that exposure to 100mg isoflavone (IF) supplement per
day for 1 year did not reduce mammographic density (Maskarinec
et al, 2003). Mammographic density is a biomarker of increased
breast cancer risk; high density increases the risk by four- to six-
fold. Further, the consumption of soy foods containing approxi-
mately 50mg IF per day for 2 years did not affect circulating
steroid hormones or sex hormone-binding protein (Maskarinec
et al, 2004), and thus the proposed reduction in breast cancer risk
by soy cannot be explained through its effects on serum hormone
levels in adults.
One possible explanation for the discrepancy between the
protective role of soy found in two meta-analyses (Trock et al,
2006; Wu et al, 2008) and the lack of effect on biomarkers of breast
cancer risk or the results generated in animal studies during adult
exposure to soy/genistein is that, to be protective, this bioactive
food component may need to be consumed during early life. In
support of this argument, epidemiological studies indicate that
childhood/adolescence exposure to soy provides protection against
breast cancer later in life (Shu et al, 2001; Wu et al, 2002). Animal
studies are in agreement with the findings obtained in humans,
and we will briefly review the data on the effects of genistein/soy
exposure in utero and/or during prepuberty on mammary
tumorigenesis in animals. Studies carried out in rats and mice
are discussed separately because the tumorigenesis models used in
the two species are different.
Rats
Several studies have examined whether an exposure to genistein
or soy protein isolate (SPI), either in utero or prepubertally, or a
combination of both, affects later mammary tumorigenesis. In
addition to genistin (the glucoside conjugate of genistein) and
genistein (the aglycone), SPI contains daidzin (the glucoside
conjugate) and daidzein (the aglycone), the other main IFs in soy.
Daidzein has weaker oestrogenic properties than genistein and
generally has not been considered responsible for the biological
actions of soy. The third IF of SPI is glycitin and its aglycone
glycitein, but they are present only at low levels.
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www.bjcancer.comTable 1 Studies carried out in rats investigating the effects of early life genistein/SPI/soy exposure on mammary gland morphology and tumorigenesis
Exposure
time
Compound/diet, dose,
route of administration
Effect on mammary
gland morphology
Effect on carcinogen-induced
mammary tumour growth Reference
In utero and perinatal exposure
GD 15–19 Genistein 1.5 or 30mgkg
 1
per day, s.c.
PND 28: no changes in TEB
number
MNU (50mgkg
 1 on PND 28):
no changes in tumour latency and
multiplicity by PND 182
Pei et al (2003)
GD 15–20 Genistein 20, 100, or 300mg
per rat per day (B0.1, 0.5,
1.5mgkg bw
 1), s.c.
Not studied DMBA (10mg per rat E50mgkg
 1
on PND 45–50): increased tumour
incidence. Follow-up until PND
170–200
Hilakivi-Clarke et al (1999)
GD 0 – PND 0 Genistein 15, 150, or 300p.p.m. in
AIN-93G diet (produces serum
levels corresponding to Asians on
high soy diet; Note 1)
PND 56: an increase in
the number of TEBs, and a
decrease in the number of
lobules in the highest genistein
group
DMBA (10mg per rat E50mgkg
 1
on PND 47): no change in tumour
latency, but increased tumour
incidence on PND 119 in the high
genistein group
Hilakivi-Clarke et al (2002)
GD 4 – PND 0 Genistein 250p.p.m. or SPI (gen
216mg+daid 160mg per kg) in
AIN-93G diet (Note 1)
Not studied MNU (50mgkg
 1 on PND 51):
longer tumour latency in both
groups, and lower tumour
multiplicity and % high-grade
tumours in SPI group on
PND 149
Su et al (2007a)
GD 0–21 Genistein 250p.p.m. in AIN-76A
diet (Note 1)
Not studied DMBA (80mgkg
 1 on PND 50):
no effect on tumour multiplicity.
Follow-up until PND 230
Lamartiniere et al (2002)
PND 2–8 Genistein 10mgkg bw
 1 per day,
s.c. (pharmacological dose; Note 1)
PND 200: distended mammary
glands with secretion and milk
production, ductal hyperplasia,
microcalcifications, fibrosis, and
necrosis
Spontaneous: increased mammary
atypical hyperplasias and in situ ductal
carcinomas of comedo type on
PND 200
Foster et al (2004)
In utero and pre/peripubertal exposure
GD 0 – PND
21
Genistein 25 or 250p.p.m. in
AIN-76A diet (250p.p.m.
produced serum levels of ca.
700 and 1800pmolml
 1
on PND 7 and 21, respectively)
PND 21 and 50: reduced number
of TEBs. PND 50: lower
number of lobules type I in the
higher
genistein group
DMBA (80mgkg
 1 on PND 50):
a dose-dependent decrease in
tumour multiplicity by PND 230
Fritz et al (1998)
GD 1 – PND
22
Genistein 300 or 800p.p.m.
in chow diet
PND 22: increased ductal
branching in the higher genistein
group in males
Not studied You L, Sar M, Bartolucci EJ,
McIntyre BS, Sriperumbudur R
(2002) Modulation of mammary
gland development in prepubertal
male rats exposed to genistein
and methoxychlor. Toxicol Sci 66:
216–225
GD 4 – PND
21, 33 or 50
20% SPI in AIN-93G diet
(Note 2)
PND 50: reduced number of
TEBs
Not studied Rowlands JC, Hakkak R, Ronis MJ,
Badger TM (2002) Altered
mammary gland differentiation and
progesterone receptor expression
in rats fed soy and whey
proteins. Toxicol Sci 70:
40–45
In utero - lifetime exposure
GD 4-PND
149
SPI (gen 216mg +daidzein
160mg per kg) in AIN-93G diet
Not studied MNU (50mgkg
 1 on PND 51):
longer tumour latency, decreased
tumour incidence and multiplicity
by PND 149
Su et al (2007a)
GD 0 -
lifetime (for
two
generations)
SPI¼430mg total isoflavones,
including 276mg genistein and
132mg daidzein per kg
AIN-93G diet
Not studied DMBA (80mgkg
 1 on PND 50:
longer tumour latency, and a
decline in tumour incidence in the
second generation. No difference
in tumour multiplicity or
volumes by PND 175
Hakkak et al (2000)
GD 7 -
lifetime
Genistein 5, 25, 100, 250, 625,
or 1250p.p.m. in chow diet
PND 50: increased lobular
differentiation, but ductal and
alveolar hyperplasia in
the higher genistein groups
Not studied Delclos KB, Bucci TJ, Lomax LG,
Latendresse JR, Warbritton A, Weis
CC, Newbold RR (2001) Effects of
dietary genistein exposure during
development on male and female
CD (Sprague–Dawley) rats. Reprod
Toxicol 15: 647–663
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Exposure
time
Compound/diet, dose,
route of administration
Effect on mammary
gland morphology
Effect on carcinogen-induced
mammary tumour growth Reference
Prepubertal exposure
PND 1–21 Genistein: 250p.p.m. in
AIN-76A diet
PND 50: reduced number of TEBs
and increased number of lobules
DMBA (80mgkg
 1 on PND 50):
reduced tumour multiplicity by
PND 230
Lamartiniere et al (2002)
PND 7, 10, 14,
17, 20
Genistein 20mg per pup per
day (ca.1mgkgbw
 1) s.c.
PND 183: increased lobular
differentiation
DMBA (10mg per rat E50mgkg
 1
on PND 45): reduced tumour
multiplicity and number of
proliferating tumours on
PND 171
Hilakivi-Clarke L, Onojafe I,
Raygada M, Cho E, Skaar T,
Russo I, Clarke R (1999)
Prepubertal exposure to zearalenone
or genistein reduces mammary
tumorigenesis. Br J Cancer 80:
1682–1688
PND 7–20 Genistein 50mg per pup per day
(ca.3.3 1.25mgkg
 1 per day) or
E2 10mg per pup per day s.c.
PND 56: genistein reduced
number of TEBs and
epithelial density, increased
number of lobuloalveolar
structures
DMBA (studied only in
prepubertally E2-exposed rats: a
significant decrease in tumour
incidence compared to
control rats)
Cabanes et al (2004)
PNDs 16, 18,
20
Genistein 500mgkg
 1 per day
(in all studies) s.c.
PND 50: reduced number of TEBs,
increased number of lobules
DMBA (80mgkg
 1 on PND 50):
reduced mammary tumour
multiplicity or incidence
Cotroneo MS, Wang J, Fritz WA,
Eltoum IE, Lamartiniere CA (2002)
Genistein action in the prepubertal
mammary gland in a
chemoprevention model.
Carcinogenesis 23: 1467–1474
Brown NM, Wang J, Cotroneo MS,
Zhao YX, Lamartiniere CA (1998)
Prepubertal genistein treatment
modulates TGF-alpha, EGF and EGF-
receptor mRNAs and proteins in the
rat mammary gland. Mol Cell
Endocrinol 144: 149–165
Murrill WB, Brown NM, Zhang JX,
Manzolillo PA, Barnes S, Lamartiniere
CA (1996) Prepubertal genistein
exposure suppresses mammary
cancer and enhances gland
differentiation in rats. Carcinogenesis
17: 1451–1457
PND 15–19 Genistein 1.5 or 30mgkgbw
 1
per day, s.c.
PND 28: no changes in TEB
number
MNU (50mgkg
 1 on PND 28):
decrease in tumour incidence
through PND 182 (low-dose
genistein)
Pei et al (2003)
PND
23,25,27,29
Genistein 50mgkgbw
 1
per day, s.c.
PND 30: increase in mammary
gland size, and the number of
lobules I, but no effect on
the TEBs
Not studied Brown NM, Lamartiniere CA (1995)
Xenoestrogens alter mammary gland
differentiation and cell proliferation in
the rat. Environ Health Perspect 103:
708–713
Peripubertal exposure
PND 31–45 Genistein 375 or 750p.p.m.
in diet
PND 45: no effects on
mammary ductal and
lobuloalveolar development
Not studied Santell RC, Chang YC, Nair MG,
Helferich WG (1997) Dietary
genistein exerts estrogeneic
effects upon the uterus,
mammary gland and the
hypothalamic/pityuitary axis in rats.
J Nutr 127: 263–269
Pre- or peripubertal-for lifetime exposure
PND 21 -
ca.218
0.35 or 0.7% soy extract
(Soyselectt, contains 12%
isoflavones) in AIN-76A diet
Not studied DMBA (80mgkg
 1 on
PND 50): longer tumour latency.
No effect on the incidence,
multiplicity, or median total tumour
burden by PND 218
Gallo et al (2001)
PND 25-158 Genistein 800 or 1600p.p.m.
in AIN-76A diet
Not studied MNU (50mgkg
 1 on PND 50):
no significant effects by PND 158
Kim H, Hall P, Smith M, Kirk M,
Prasain JK, Barnes S, Grubbs C
(2004) Chemoprevention by grape
seed extract and genistein in
carcinogen-induced mammary
cancer in rats is diet dependent.
J Nutr 134: 3445S–3452S
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SPI or purified genistein during the fetal-perinatal period vary
from study to study, with three studies reporting an increase in the
incidence of either carcinogen-induced tumours (Hilakivi-Clarke
et al, 1999; Hilakivi-Clarke et al, 2002) or spontaneous hyper-
plasias and ductal carcinomas in situ (Foster et al, 2004), one study
reporting a reduction in tumour multiplicity and % high grade
tumours (Su et al, 2007a), and two studies reporting no effects
(Lamartiniere et al, 2002; Pei et al, 2003). Two of these studies
investigated the effects on mammary gland morphology in adult
rats (Hilakivi-Clarke et al, 2002; Foster et al, 2004). In one study,
genistein increased the number of terminal end buds (TEBs)
(Hilakivi-Clarke et al, 2002), and the other study showed that
genistein induced ductal hyperplasias (Foster et al, 2004). TEBs
have at least two key functions: (1) they are located at the tips of
growing ducts and lead the invasion of the epithelial tree to fill the
mammary fat pad; (2) they are the sites where malignant
transformation takes place (Hilakivi-Clarke, 2007). TEB number
peaks after puberty onset at 1 month of age, and they disappear
when the epithelial tree has filled the fat pad at 2 months of age.
The corresponding structures in the human mammary gland are
terminal ductal lobular units (Cardiff, 1998), of which 90% of
human breast cancers originate.
Studies examining whether an exposure to soy/SPI/genistein,
which started at conception and continued until weaning, affects
mammary tumorigenesis found a reduction in tumour multiplicity
(Fritz et al, 1998; Table 1). Two groups have examined the effects
of SPI exposure, which began during gestation and continued
throughout adulthood on mammary tumorigenesis, reporting a
reduction in mammary tumour incidence and/or multiplicity
(Hakkak et al, 2000; Su et al, 2007a). Interestingly, the study by
Hakkak et al (2000) found a decline in tumour incidence only
in the second generation. The data regarding prepubertal exposure
to genistein are very consistent in showing a reduction in
mammary cancer risk. Table 1 indicates that all studies
investigating an effect on mammary tumorigenesis report a
reduction in risk in rats exposed to genistein via feed or through
subcutaneous administration. The effects of genistein exposure on
mammary gland morphology have been recently reviewed by
Warri et al (2007), and they are consistent with the protective
effect. All studies that investigated mammary gland morphology at
the time the gland is most susceptible to malignant transformation
indicate a reduction in the number of TEBs and an increase in
lobular differentiation (Table 1).
A human parallel to the early life (neonatal) animal studies
exists, infants exposed to soy formula. This exposure parallels an
exposure during the first 3 weeks of life in rodents. However, at the
present time, it is not known whether the high perinatal soy
exposure among infant soy formula users has any effect on later
breast cancer risk. The conclusions reached in reviews discussing
the safety of infant soy formula suggest that it does not appear to
cause adverse general health or reproductive outcomes or affect
human growth (Strom et al, 2001). More cautious authors propose
that the existing data are insufficient to draw definitive con-
clusions on safety and that the use of soy protein formulae should
be limited only to those who cannot consume casein-based
formulas (Turck, 2007).
Studies that have investigated whether lifetime exposure that
begins at puberty has any effects have generated opposing findings
(Table 1). Only one of the five studies that exposed rats to genistein
or SPI found any effect on mammary tumour incidence or
multiplicity (Constantinou et al, 2001), and two studies reported a
longer tumour latency (Constantinou et al, 2001; Gallo et al, 2001).
The study of Constantinou et al (2001) found that an exposure to
SPI that was depleted of IFs had the most significant effect on
tumour latency and multiplicity. Also, an exposure to 10% miso
Table 1 (Continued)
Exposure
time
Compound/diet, dose,
route of administration
Effect on mammary
gland morphology
Effect on carcinogen-induced
mammary tumour growth Reference
PND 36-127 Isoflavones: 30400810 p.p.m.
in SPI containing diet
Not studied DMBA (10mg per rat on PND 50):
no significant effects by PND 127
Appelt LC, Reicks MM (1999)
Soy induces phase II enzymes
but does not inhibit
dimethylbenz[a]anthracene-induced
carcinogenesis in female rats. J Nutr
129: 1820–1826
PND 43-
ca.176 (F-344
rats)
10 or 20% SPI, with and without
isoflavones, in AIN-93G (Note 2)
Not studied MNU (40mgkg
 1 on PND 50): no
significant effects by PND 176
Cohen LA, Zhao Z, Pittman BSJA
(2000) Effect of intact and isoflavone-
depleted soy protein on NMU-
induced rat mammary tumorigenesis.
Carcinogenesis 21: 929–935
PND 43-
ca.163
Genistein 200p.p.m. or
16% SPI with and without
isoflavones, in modified AIN-74A
diet (Note 2)
Not studied DMBA (15mg per rat on PND 50):
decreased tumour multiplicity with
SPI, but not with genistein. Most
significant effect on tumour
multiplicity and latency in the SPI-
without isoflavones group
Constantinou et al (2001)
PND 49-175
(CD/Crj rats)
10% miso (fermented soybean
product) in diet
Not studied MNU (50mg per rat on PND 49):
significant decrease in incidence and
multiplicity by PND 175
Gotoh et al (1998)
Abbreviations: bw¼body weight; DMBA¼dimethylbenz(a)anthracene; GD¼gestational day; MNU¼N-methyl-n-nitrosourea; PND¼postnatal day; p.p.m.¼parts per million
(mg per kg); SPI¼soy protein isolate; TEB¼terminal end bud. Note 1: Asian population on high soy diet consumes genistein ca. 1–30mg per day¼ca. 0.02–0.55mgkg
 1 per
day. Native Japanese adults are reported typically to consume 30–40mg (aglycone units) of isoflavones per day (Wakai et al J Nutr 1998; 128: 209–213), their plasma levels
being B300nmoll
 1 (Adlercreutz et al Lancet 1993; 342: 1209–1210). Genistein intake in the Western Europe ca. 0.005mgkg
 1 per day. For extrapolation from human to
rodent, small animals need ca. 10 times higher concentrations compared to humans, since they are less susceptible to drugs (Wuttke et al Ageing Res Rev 2007; 6(2): 150–88).
Thus, genistein doses 0.1–1.5mgkg
 1 per day to rodents would be comparable to average daily intake in Asian countries. Doses 410mgkg
 1 per day are pharmacological.
Note 2: SPI contains the isoflavones genistein 216mgkg
 1, and daidzein 160mgkg
 1, and their b-glycosides (Hakkak et al Cancer Epidemiol Biomarkers Prev 2000; 9: 113–117).
SPI (10 and 20%) is estimated to contain ca. 50 and 100 times the intake of an average Japanese adult (Cohen et al Carcinogenesis 2000; 21(5): 929–935). Note 3: Sprague–
Dawley rats were used unless otherwise stated in the first column, under the ‘exposure time’.
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et al, 1998).
To summarise, genistein/SPI exposure limited to the prepubertal
period appears to reduce later mammary cancer risk in rats, but
the effect is mostly lost if the exposure remains high throughout
adult life. It is noteworthy, however, that the genistein/SPI
formulations and routes of administration in different studies
varied (injected vs in the diet), which makes it difficult to draw
definitive conclusions by comparing results of these studies.
However, although genistein/SPI exposure in utero may increase
susceptibility to malignant transformation, if the exposure
continues to adulthood a reduction in risk may occur. The latter
is consistent with low breast cancer risk among Asian women who
are exposed to soy throughout their lifetime, suggesting that
in utero exposure primes the gland for later protective effects of
genistein. Why a similar reduction in risk is not seen in rats in
which exposure started postnatally and continued through the rest
of the study is not clear.
Mice
Studies on the effects of genistein/soy on mammary tumorigenesis
in mouse models are scarce, and all studies but one have used a
transgenic mouse model in which tumours are caused by an
oncogene expressed in the mammary gland during embryogenesis
(Table 2). Further, the mouse studies are more diverse than the rat
studies concerning the age when the mammary gland morphology
was studied. The findings obtained in these studies show that mice
exposed to genistein during fetal development exhibit an increase
in the number of TEBs as adults (reviewed by Warri et al, 2007).
According to different studies, neonatal and/or pubertal genistein/
SPI exposure either increases (Luijten et al, 2004; Thomsen et al,
2005) or reduces (Yang et al, 2003) epithelial differentiation.
No studies have examined the effects of exposures to genistein/
soy that were limited to the fetal or prepubertal period on
mammary tumorigenesis. Only one study in mice has investigated
whether an exposure from conception until puberty to soy IFs
Table 2 Studies carried out in mice investigating the effects of early life genistein/soy exposure on mammary gland morphology and tumorigenesis
a
Mouse strain,
exposure time
Compound/diet, dose, route of
administration
Effect on mammary gland
morphology
Effect on oncogene- or
carcinogen-induced mammary
tumour growth Reference
In utero exposure (no studies)
In utero and prepubertal exposure
FVB/N-TgN
(MMTV-neu), GD
0 – PND 21–23
‘Prevastein’ containing (1) genistein
6mg+no daidzein, or (2) genistein
28mg+daidzein 12mg, or (3) genistein
89mg+daidzein 42mg per kg
high fat diet
PND 70: enhanced mammary gland
‘maturation’ (decreased number of
TEBs) in the highest dose group
No change in tumour onset.
Increase in tumour burden
(multiplicity and mass) in the medium
and high isoflavone groups. Follow-up
until PND 140
Luijten et al
(2004)
Prepubertal exposure (no studies)
Pre- or peripubertal -for lifetime exposure
aERKO and WT
mice (C57Bl/
6J 129SVJ), PND
21-lifetime
Genistein 1000p.p.m. in AIN-76A diet Not studied MPA-DMBA
b: no significant effects by
PND 238
Day et al
(2001)
FVB/N-TgN
(MMTV/c-neu),
PND 25–196
Soy isoflavones (prevastein): 11, 39, 130mg
per kg high fat (Western style) diet
PND 70: increased mammary ductal
branching (all doses, PND 42) and
decreased number of TEBs in
the medium dose group
No change in tumour incidence.
Increase in tumour multiplicity
and size (highest dose group)
by PND 196
Thomsen et al
(2005)
TG.NK (MMTV/
c-neu), PND
28–210
Open formula (soy, alfaalfa, wheat, oat,
corn) NTP-2000 diet vs AIN-76A
Not studied Open formula diet significantly
decreased tumour incidence,
multiplicity and tumour
weight compared to AIN-76A
(follow-up until PND 210)
Rao et al
(1997)
FVB/N-TgN
(MMTV/c-neu),
PND 28-lifetime
SPI including genistein 132mg+daidzein
89mg per kg high fat (Western style) diet
Not studied No significant effects by PND 238 Luijten et al
(2004)
FVB/N-TgN
(MMTV/c-neu),
starting on PND
28–35-lifetime
23.4% soy meal, including genistein
214p.p.m. and daidzein
277p.p.m. in Purina 5001 diet
PND 175: reduced mammary ductal
elongation and branching
(descriptive data). Potentiation of the
precocious differentiation by E of the
mammary gland (descriptive data)
Longer tumour latency. (Necropsy on
PNDs 105, 140, 175, 224,
266, 315, and 420)
Yang et al
(2003)
FVB/N-TgN
(MMTV/c-neu),
starting on PND
28–35-lifetime
Soy meal (Purina 5001) diet including
genistein 214mg and daidzein 277mg per
kg diet, or diet with pure genistein 137mg
and daidzein 74mg per kg diet
Not studied Decrease in incidence in soy
meal group (follow-up
until PND 420)
Liu et al (2005)
FVB/N-TgN
(MMTV/c-neu),
starting on PND
42–49-lifetime
Genistein: 250mg, or NovaSoy with
genistein 250mg per kg AIN-93G+the
mice were mated and allowed one full-
term pregnancy and 2 weeks of lactation
during the first 3 month of life
Not studied Longer tumour latency by both genistein
and NovaSoy. No changes in tumour
incidence or multiplicity by PND 238
Jin and
MacDonald
(2002)
Abbreviations: DMBA¼dimethylbenz(a)anthracene; GD¼gestational day; MPA¼medroxyprogesterone acetate; MNU¼N-methyl-n-nitrosourea; PND¼postnatal day;
SPI¼soy protein isolate; TEB¼terminal end bud.
aTumour models: spontaneous mammary tumour model of transgenic mice (MMTV/c-neu), and a DMBA-induced, MPA-
primed mouse mammary tumour model (MPA-DMBA).
bMedroxyprogesterone acetate – priming with 2 20mg pellets on week 7, DMBA 1mg single dose orally on weeks 9,
10, 12, and 13.
Early life genistein exposures in modifying breast cancer risk
A Warri et al
1489
British Journal of Cancer (2008) 98(9), 1485–1493 & 2008 Cancer Research UKaffects mammary tumorigenesis (Table 2; Luijten et al, 2004).
The study found that Prevastein
s, an IF concentrate, not
only increased mammary tumour multiplicity and burden
but also accelerated mammary gland development (Luijten et al,
2004). This observation is opposite to the findings obtained
in rats showing that an exposure from conception to
weaning is protective against carcinogen-induced mammary
tumours.
There are a total of seven studies carried out in mice that were
fed SPI or soy meal from the prepubertal period onwards, until the
tumour monitoring was completed (Table 2). The studies reported
that the exposure reduced (Rao et al, 1997; Liu et al, 2005),
increased (Thomsen et al, 2006), or had no effect (Day et al, 2001;
Jin and MacDonald, 2002; Luijten et al, 2004) on mammary
tumour incidence and/or multiplicity and size. In addition, a
delayed tumour onset after genistein or soy exposure was reported
in two of the six genetically modified mouse studies (Jin and
MacDonald, 2002; Yang et al, 2003). Thus, the data obtained
through studies carried out in mice conflict with each other, and it
is not clear whether the diversity in outcome can be explained by
differences in the route of administration, doses used, or the type
of exposure (genistein vs SPI vs soy meal). Furthermore, studies
carried out using rats and mice differ by the model systems used
(carcinogen-induced in rats or oncogene-driven in mice) and the
differences in mammary gland morphology and oestrogen
responsiveness of the established tumours (responsive in rats or
non-responsive in mice), which can explain why the data
generated in the rat and mouse studies are diverse. Whether these
findings can be explained by the oestrogenicity of genistein
remains to be investigated.
MECHANISMS
Two types of changes in the mammary glands of individuals
exposed to genistein early in life may mediate the effects on later
cancer risk: alterations in gene expression and morphological
changes. It is most likely that both are involved and that they
interact with each other; that is, changes in gene expression affect
morphology and vice versa. In addition, it is possible that the
better bioavailability of IFs in children, compared to adults (Halm
et al, 2007), affects the findings.
As discussed above, the effects of early life genistein exposures
on mammary gland morphology and the developmental stage,
when animals were examined, vary from study to study, making it
difficult to tie the changes in the morphology to observed or
anticipated changes in mammary tumorigenesis. An exception is
prepubertal exposure to genistein: all the studies carried out,
showing a reduction in mammary tumorigenesis in rats, also
report consistent changes in mammary gland morphology. This
exposure induces differentiation of the mammary epithelium by
eliminating TEBs and increasing the number of differentiated
lobular-alveolar structures (Table 1). These morphological changes
may be initiated by genistein-induced alterations in the mammary
stem cell number and/or fate. Of the various epithelial structures,
TEBs are believed to contain the highest number of mammary
stem cells (Woodward et al, 2005).
Stem cells
During mammary gland development, many stem and progenitor
cells gradually commit to differentiation pathways, but some
remain uncommitted or partly differentiated within the mammary
tissue (Smalley and Ashworth, 2003). Both the stem cell number
and their fate may be determined during critical windows of
mammary gland development; that is, during in utero period,
puberty, and pregnancy. The hormonal environment associated
with these stages might affect breast cancer risk by increasing or
reducing the total number of replicating stem cells, their lineage-
specific differentiation to myoepithelial and luminal cells, and
eventually the number of cells at risk for malignant transformation
(Trichopoulos et al, 2005). There is accumulating evidence for the
hypothesis that breast cancer risk is determined in part by the
number of susceptible breast stem/progenitor cells that can serve
as targets for transformation (Liu et al, 2008).
Stem cells have been linked to pregnancy-induced dual
effects on breast cancer risk. Although pregnancy, pregnancy
hormonal environment, and soy exposures during pregnancy
in affecting mother’s risk are not discussed in this review, the
mechanisms by which pregnancy alters susceptibility to develop
breast cancer may be relevant in explaining the protective
effects of prepubertal genistein and oestrogen exposures. We
(Cabanes et al, 2004) and others have shown that peripubertal
oestrogen exposure reduces mammary gland tumorigenesis in
animal models. According to Sivaraman et al (1998),
pregnancy hormones induce a molecular switch in mammary
stem cells that inhibits cell proliferation in response to
subsequent exposure to hormones or carcinogens. Wagner and
Smith (2005) have identified cells in the mammary gland that are
likely to represent pregnancy-related epithelial cells (PI-MECs)
with stem cell characteristics. These investigators have suggested
that the PI-MECs, which do not undergo apoptosis during post-
lactational remodelling and thus persist the rest of the (mouse’s)
life after the first pregnancy–lactation cycle, could be the
mediators of the long-term pregnancy-related protective effects
against breast cancer (Wagner and Smith, 2005). However, in a
transgenic mouse model prone to pregnancy-related mammary
tumorigenesis (MMTV-neu mice), the PI-MECs may be the targets
for neoplastic transformation (Wagner and Smith, 2005), under-
lining the complexity of mammary stem cells and their role in
malignant transformation. Several excellent papers have been
published regarding the effects of pregnancy on gene expression,
and clearly some of the changes induced by pregnancy
and pubertal genistein exposure are similar, such as upregulation
of BRCA1 and p53 (Cabanes et al, 2004; de Assis and
Hilakivi-Clarke, 2006).
Changes in cell proliferation and apoptosis
If an early life exposure to genistein, or other oestrogenic
compounds, alters breast cancer risk by targeting epithelial stem
or progenitor cells, changes in cell proliferation and apoptosis are
expected to be seen. For example, a higher number of stem cells in
individuals exposed to oestrogenic compounds in utero, or to diets
that increase later mammary cancer risk, might be associated with
increased cell proliferation, either by inducing proliferation or by
reflecting a need for stem cells to fullfil the demand of increasing
the number of luminal and myoepithelial mammary cells to form
TEBs, lobules and ducts. An illustrative example is caveolin-1
knockout mice, which exhibit dysregulation of mammary stem cell
self-renewal, probably due to increased Wnt/b-catenin signalling
(Sotgia et al, 2005).
Fetal exposure to genistein has been reported to increase mitotic
activity in the mammary gland (Foster et al, 2004), which is
consistent with the findings linking this exposure to increased risk
of developing mammary tumours. The effects of prepubertal
genistein exposure on cell proliferation in rats are also consistent
with the effects on tumorigenesis. When determined using the
heavy water labelling method (Kim et al, 2007) or by labelling
the cells with Brdu (Pei et al, 2003), exposure to genistein in the
prepubertal period inhibited mammary epithelial cell proliferation.
If the genistein exposure continues to adulthood, it may impact
neither cell proliferation nor apoptosis (Gallo et al, 2002), again in
agreement with the findings regarding the effects on mammary
tumorigenesis.
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The means by which hormonal changes would affect stem cells
might be due to changes in gene expression. As an attempt to
define the key changes in mammary reprogramming by hormones,
an extensive list of genes attributed to mammary stem cells has
been presented (Woodward et al, 2005). To summarise, stem cell
fate, that is self-renewal and differentiation along specific lineage
pathways, is regulated by multiple factors. In the mammary gland,
Wnt/b-catenin, Notch and Hedgehog signalling pathways impact
mammary stem/progenitor cell fate. BRCA1 (Sotgia et al, 2005)
and phosphatase and tensin homologue deleted on chromosome
10 (PTEN) (Stiles et al, 2004) may also be involved. In particular,
BRCA1 is suggested to play a critical role in the differentiation
of oestrogen receptor (ER)-negative stem/progenitor cells to
ER-positive luminal cells (Liu et al, 2008). As discussed below,
genistein affects the expression of some of the genes that regulate
mammary stem cell fate.
Many of these changes in gene expression induced by genistein
reflect the chemical structure of this phytochemical and thus the
activation of the ERs, but some are due to genistein’s ability to
inhibit several protein kinases. Interestingly, the effects of
genistein on the ER expression are variable between different
studies, with some reporting a reduction (Pei et al, 2003) and some
an increase in the ER-a levels (Su et al, 2007a). Studies are
relatively consistent in showing an upregulation of ER-b by
genistein. Oestrogen receptors may be linked to stem cells,
although it is not clear whether mammary stem cells express or
do not express this receptor.
It is difficult to determine the importance of the genes identified
in microarray studies in human breast cancer cells in mediating
the preventive effects of genistein, as the changes may not have a
direct impact on altering the susceptibility to mammary tumor-
igenesis. A recent microarray study, which used the mammary
glands of adult rats exposed to genistein via diet from conception
onwards, identified several genes that relate to stem cell fate and/or
regulate mammary cell proliferation, apoptosis and differentiation,
including increased expression of Sfrp2 (Wnt receptor) and Hes1
(Notch signalling pathway), and reduced expression of Wnt5a and
Notch2 (Su et al, 2007b). Since this exposure was also reported to
lengthen tumour latency and reduce tumour incidence and
multiplicity (Su et al, 2007a), it is possible that genistein/SPI
reduces mammary cancer risk by affecting stem cell fate.
GENISTEIN AND TUMOUR SUPPRESSOR GENES
It is clear that no single genetic change is responsible for the
initiation of all breast cancers, but this disease can have a highly
varying genetic background. Alterations in the expression of
tumour suppressor genes, either by mutations or directly/
indirectly due to epigenetic changes, are particularly critical in
affecting breast cancer risk. We will briefly review two tumour
suppressor genes whose expression is altered in animals exposed
to genistein: they are BRCA1 and PTEN.
BRCA1
Hereditary mutations in BRCA1 not only increase the risk of breast
cancer but also risk for ovarian and prostate cancer. Women who
have inherited mutations in the BRCA1 tumour suppressor gene
have an approximately 66% likelihood of developing breast cancer
by the age of 70 (Friedenreich et al, 2001). In sporadic breast
cancers, BRCA1 mutations are rare; however, 30–40% of sporadic
cancers show reduced expression of BRCA1 (see Ashworth, 2004).
BRCA1 has many biological functions. This protein interacts
with RAD51 protein (Ashworth, 2004) and, as a result, BRCA1 is
capable of acting as a gatekeeper in maintaining genomic integrity
by preventing DNA damage and inducing DNA repair. The C
terminus of BRCA1 interacts with several transcription factors and
thus can regulate basal transcriptional machinery. The importance
of BRCA1 for normal mammary development has been demon-
strated through a transgenic mouse model, this model expresses a
splice variant of BRCA1, which lacks the N-terminal RING finger
domain (MMTV-BRCA1sv) (Hoshino et al, 2007). The Brca1
mutant mice exhibited enhanced TEB proliferation at puberty and
marked mammary lobulo-alveolar development, and they had an
increased tumorigenesis and accelerated mortality after a challenge
by DMBA.
Several findings indicate a link between genistein and BRCA1,
although most of the studies focus either on genistein’s direct
effects on BRCA1 (in vitro) or its effects on BRCA1 in adult
animals. In vitro studies have shown that physiological doses of
genistein (0.5–1.0mM) upregulate BRCA1 in ERþ human breast
cancer cells and in prostate cancer cells (Fan et al, 2006). In
addition, genistein upregulates the expression of both Brca1 and
Brca2 mRNA in adult ovariectomised rats (Vissac-Sabatier et al,
2003). However, the findings obtained in mice inoculated with
mammary tumour cells obtained from conditional Brca1 /  mice,
showing that dietary exposure to 750p.p.m. genistein reduced the
size of the tumours by 50%, indicate that genistein can be
protective in the absence of functional Brca1 (Tominaga et al,
2007). The potential protective effect of pubertal genistein
exposure may be linked to an upregulation of Brca1: we noted
that this tumour suppressor is upregulated in the mammary glands
of rats exposed daily to 50mg genistein or 10mg E2 during
prepuberty (Cabanes et al, 2004). Ongoing studies in our
laboratory are determining whether prepubertal exposure to
500p.p.m. genistein affects mammary tumorigenesis in hetero-
zygous Brca1þ/  mice.
Phosphatase and tensin homologue deleted on
chromosome 10 (PTEN)
Inactivating mutations or deletions of the PTEN gene are among
the most common changes found in human cancers, particularly in
prostate and endometrial cancers (Blanco-Aparicio et al, 2007).
Downregulation in PTEN expression or signalling has also been
identified in several other types of cancers, including inherited and
sporadic breast cancers. The PTEN protein is a lipid phosphatase
and has been suggested to act as a tumour suppressor owing to its
inhibition of the PI3K/Akt signalling pathway. A recent microarray
analysis, comparing endometrial tissues obtained from Ptenþ/ 
and wild-type mice, identified ER and its downstream targets as
genes that might be linked to the increased endometrial cancer risk
(Lian et al, 2006). Interestingly, PTEN may be one of the key genes
BRCA1 has to repair to prevent malignant transformation:
frequent gross PTEN mutations, involving intragenic chromosome
breaks, inversions, deletions and microcopy number aberrations
are found in BRCA1-deficient tumours (Saal et al, 2008).
A study carried out utilising rats found that genistein promotes
apoptosis in mammary epithelial cells by inducing PTEN (Dave
et al, 2005). These changes were accompanied by a decrease in
mammary tumorigenesis. Fetal exposure to genistein or SPI at
doses that had no effect on mammary tumorigenesis did not affect
Pten protein expression or apoptosis in the TEBs of adult rats
(Su et al, 2007a). However, if the exposure to genistein or SPI
continued throughout the postnatal life, PTEN immunostaining
and apoptosis were increased in the mammary TEBs (Dave et al,
2005).
EPIGENETICS
The mechanisms responsible for persistent changes in gene
expression in the mammary glands of individuals exposed to
genistein or other (oestrogenic) compounds early in life are most
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or other events that cause alterations in the DNA sequence,
epigenetic changes cause alterations in gene transcription; that is
they determine whether a gene is expressed or not. Two of the best
characterised means of epigenetic modifications are DNA methy-
lation and histone modifications (Tang and Ho, 2007). Epigenetics
is now known to be the key process during early development that
allows the environment to interact with the genotype, resulting in
the observed phenotype. Thus, early life dietary exposures may
modify later breast cancer risk through epigenetic changes that
alter the pathways that participate in regulating mammary gland
development.
Genistein has been reported to affect DNA methylation (Dolinoy
et al, 2006). Methylation prevents gene expression, while
demethylation leads to increased expression of previously
methylated genes. Interestingly, genistein might both methylate
and demethylate genes. The evidence that genistein induces
methylation comes from studies showing that maternal exposure
to genistein increases methylation of six cytosine-guanine sites at
the viable yellow Agouti mice (Dolinoy et al, 2006), increasing the
number of Agouti offspring that exhibit pseudoagouti phenotype,
which in turn is linked to lowered cancer risk. However, genistein
inhibits DNA methyltransferases (Day et al, 2002), which catalyse
the addition of a methyl group, causing demethylation of the CpG
islands. It is not known whether prepubertal genistein exposure
might increase or reduce methylation patterns.
CONCLUSIONS
The evidence obtained both in epidemiological (Shu et al, 2001;
Wu et al, 2002) and animal studies (Tables 1 and 2) suggests that
genistein/soy exposure during the period preceding puberty
reduces later susceptibility to develop breast cancer. Further, if
the exposure occurs during the fetal period, no protection may be
seen, but if it continues from conception onwards, genistein/soy
may be protective. At the present time, no convincing explanation
can be offered as to why the breast cancer risk-reducing effect of
genistein/soy might be strongest during childhood and early
adolescence. One possibility is that it is linked to increased
differentiation of the mammary gland and elimination of targets
that are the sites of malignant transformation (i.e., TEBs and
mammary stem/progenitor cells). Thus, early genistein/soy
exposure might have similar effects on the mammary gland than
early pregnancy does. It is well established that early first
pregnancy (before 20 years of age) reduces breast cancer risk,
while women undergoing their first pregnancy after age 35 are at
an increased risk.
The reduction in breast cancer risk induced by early genistein/
soy exposure is also likely to reflect changes in the expression of
multiple genes. For example, in animal models, prepubertal
exposure to genistein causes a persistent upregulation of Brca1
(Cabanes et al, 2004) and it might upregulate PTEN (Dave et al,
2005). It is not known whether all these changes (or none of them)
lead to a reduction in mammary cancer risk. The complexity
between genistein/soy, the genes it activates/inhibits, and breast
cancer risk are also illustrated by the fact that genistein activates
ER-a, which in turn interacts with BRCA1 (Fan et al, 2006) and
PTEN (Lian et al, 2006). The causality between the changes in gene
expression induced by genistein/soy intake and altered breast
cancer risk can be addressed at least partly by using genetically
modified mouse models such as Brca1 or Pten knockout mice.
ACKNOWLEDGEMENTS
This work was supported by grants from NCI U54 CA0010097*0
(LHC and SM), NIEHS R21ES13858-3 (LHC) and the Academy of
Finland (NMS).
REFERENCES
Ashworth A (2004) Refocusing on BRCA1. Nat Cell Biol 6: 916–917
Blanco-Aparicio C, Renner O, Leal JF, Carnero A (2007) PTEN, more than
the AKT pathway. Carcinogenesis 28: 1379–1386
Cabanes A, Wang M, Olivo S, de Assis S, Gustafsson JA, Khan G,
Hilakivi-Clarke L (2004) Prepubertal estradiol and genistein exposures
up-regulate BRCA1 mRNA and reduce mammary tumorigenesis.
Carcinogenesis 25: 741–748
Cardiff RD (1998) Are the TDLU of the human the same as the LA of mice?
J Mammary Gland Biol Neoplasia 3: 3–5
Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB,
Pezzuto JM (2001) Chemopreventive effects of soy protein and purified
soy isoflavones on DMBA-induced mammary tumors in female
Sprague–Dawley rats. Nutr Cancer 41: 75–81
Dave B, Eason RR, Till SR, Geng Y, Velarde MC, Badger TM, Simmen RC
(2005) The soy isoflavone genistein promotes apoptosis in mammary
epithelial cells by inducing the tumor suppressor PTEN. Carcinogenesis
26: 1793–1803
Day JK, Bauer AM, DesBordes C, Zhuang Y, Kim BE, Newton LG, Nehra V,
Forsee KM, MacDonald RS, Besch-Williford C, Huang TH, Lubahn DB
(2002) Genistein alters methylation patterns in mice. J Nutr 132:
2419S–2423S
Day JK, Besch-Williford C, McMann TR, Hufford MG, Lubahn DB,
MacDonald RS (2001) Dietary genistein increased DMBA-induced
mammary adenocarcinoma in wild-type, but not ER alpha KO, mice.
Nutr Cancer 39: 226–232
de Assis S, Hilakivi-Clarke L (2006) Timing of dietary estrogenic exposures
and breast cancer risk. Ann NY Acad Sci 1089: 14–35
Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL (2006) Maternal
genistein alters coat color and protects avy mouse offspring from obesity
by modifying the fetal epigenome. Environ Health Perspect 114: 567–572
Fan S, Meng Q, Auborn K, Carter T, Rosen EM (2006) BRCA1 and
BRCA2 as molecular targets for phytochemicals indole-3-carbinol
and genistein in breast and prostate cancer cells. Br J Cancer 94:
407–426
Foster WG, Younglai EV, Boutross-Tadross O, Hughes CL, Wade MG
(2004) Mammary gland morphology in Sprague–Dawley rats following
treatment with an organochlorine mixture in utero and neonatal
genistein. Toxicol Sci 77: 91–100
Friedenreich CM, Courneya KS, Bryant HE (2001) Influence of physical
activity in different age and life periods on the risk of breast cancer.
Edidemiology 12: 604–612
Fritz WA, Coward L, Wang J, Lamartiniere CA (1998) Dietary genistein:
perinatal mammary cancer prevention, bioavailability and toxicity
testing in the rat. Carcinogenesis 19: 2151–2158
Gallo D, Ferrandina G, Giacomelli S, Fruscella E, Zannoni G, Morazzoni P,
Riva A, Bombardelli E, Mancuso S, Scambia G (2002) Dietary soy
modulation of biochemical parameters in DMBA-induced mammary
tumors. Cancer Lett 186: 43–48
Gallo D, Giacomelli S, Cantelmo F, Zannoni GF, Ferrandina G, Fruscella E,
Riva A, Morazzoni P, Bombardelli E, Mancuso S, Scambia G (2001)
Chemoprevention of DMBA-induced mammary cancer in rats by dietary
soy. Breast Cancer Res Treat 69: 153–164
Gotoh T, Yamada K, Yin H, Ito A, Kataoka T, Dohi K (1998)
Chemoprevention of N-nitroso-N-methylurea-induced rat mammary
carcinogenesis by soy foods or biochanin A. Jpn J Cancer Res 89:
137–142
Hakkak R, Korourian S, Shelnutt SR, Lensing S, Ronis MJ, Badger TM
(2000) Diets containing whey proteins or soy protein isolate protect
against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in
female rats. Cancer Epidemiol Biomarkers Prev 9: 113–117
Early life genistein exposures in modifying breast cancer risk
A Warri et al
1492
British Journal of Cancer (2008) 98(9), 1485–1493 & 2008 Cancer Research UKHalm BM, Ashburn LA, Franke AA (2007) Isoflavones from soya foods are
more bioavailable in children than adults. Br J Nutr 98: 998–1005
Hilakivi-Clarke L (2007) Nutritional modulation of terminal end buds: its
relevance to breast cancer prevention. Curr Cancer Drug Targets 7:
465–474
Hilakivi-Clarke L, Cho E, Cabanes A, DeAssis S, Olivo S, Helferich W,
Lippman ME, Clarke R (2002) Dietary modulation of pregnancy estrogen
levels and breast cancer risk among female rat offspring. Clin Cancer Res
8: 3601–3610
Hilakivi-Clarke L, Cho E, Onojafe I, Raygada M, Clarke R (1999) Maternal
exposure to genistein during pregnancy increases carcinogen-induced
mammary tumorigenesis in female rat offspring. Oncol Rep 6: 1089–1095
Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der MR,
Shyr Y, Holt JT, Moses HL, Jensen RA (2007) Effects of BRCA1 transgene
expression on murine mammary gland development and mutagen-
induced mammary neoplasia. Int J Biol Sci 3: 281–291
Jin Z, MacDonald RS (2002) Soy isoflavones increase latency of
spontaneous mammary tumors in mice. J Nutr 132: 3186–3190
Kim HA, Jeong KS, Park DH, Lee JA, Jeong WI, Kim YK (2007) Heavy water
labeling method for measuring the effect of genistein on mammary gland
carcinogenesis. Mol Cell Biochem 301: 201–208
Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R,
Elgavish A (2002) Genistein chemoprevention: timing and mechanisms
of action in murine mammary and prostate. J Nutr 132: 552S–558S
Lian Z, De LP, Di CA (2006) Gene expression analysis reveals a signature of
estrogen receptor activation upon loss of Pten in a mouse model of
endometrial cancer. J Cell Physiol 208: 255–266
Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K,
McKimmey C, Liu N, Thor A (2005) Low-dose dietary phytoestrogen
abrogates tamoxifen-associated mammary tumor prevention. Cancer Res
65: 879–886
Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD,
Dontu G, Wicha MS (2008) BRCA1 regulates human mammary stem/
progenitor cell fate. Proc Natl Acad Sci USA 105(5): 1680–1685
Luijten M, Thomsen AR, van den Berg JA, Wester PW, Verhoef A,
Nagelkerke NJ, Adlercreutz H, van Kranen HJ, Piersma AH, Sorensen IK,
Rao GN, van Kreijl CF (2004) Effects of soy-derived isoflavones and a
high-fat diet on spontaneous mammary tumor development in Tg.NK
(MMTV/c-neu) mice. Nutr Cancer 50: 46–54
Maskarinec G, Franke AA, Williams AE, Hebshi S, Oshiro C, Murphy S,
Stanczyk FZ (2004) Effects of a 2-year randomized soy intervention on
sex hormone levels in premenopausal women. Cancer Epidemiol
Biomarkers Prev 13: 1736–1744
Maskarinec G, Williams AE, Carlin L (2003) Mammographic densities in a
one-year isoflavone intervention. Eur J Cancer Prev 12: 165–169
Pei RJ, Sato M, Yuri T, Danbara N, Nikaido Y, Tsubura A (2003) Effect of
prenatal and prepubertal genistein exposure on N-methyl-N-nitrosourea-
induced mammary tumorigenesis in female Sprague–Dawley rats.
In Vivo 17: 349–357
Rao GN, Ney E, Herbert RA (1997) Influence of diet on mammary cancer in
transgenic mice bearing an oncogene expressed in mammary tissue.
Breast Cancer Res Treat 45: 149–158
Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J,
Jonsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S,
Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP,
Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R,
Borg A (2008) Recurrent gross mutations of the PTEN tumor suppressor
gene in breast cancers with deficient DSB repair. Nat Genet 40: 102–107
Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT,
Zheng W (2001) Soyfood intake during adolescence and subsequent risk
of breast cancer among Chinese women. Cancer Epidemiol Biomarkers
Prev 10: 483–488
Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely
OM, O0Malley BW, Medina D (1998) Hormone-induced refractoriness to
mammary carcinogenesis in Wistar–Furth rats. Carcinogenesis 19:
1573–1581
Smalley M, Ashworth A (2003) Stem cells and breast cancer: A field in
transit. Nat Rev Cancer 3: 832–844
Sotgia F, Williams TM, Cohen AW, Minetti C, Pestell RG, Lisanti MP (2005)
Caveolin-1-Deficient Mice Have An Increased Mammary Stem Cell
Population with Upregulation of Wnt/beta-Catenin Signaling. Cell Cycle
4(12): 1808–1816
Stiles B, Groszer M, Wang S, Jiao J, Wu H (2004) PTENless means more.
Dev Biol 273: 175–184
Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA,
Stallings VA, Drulis JM, Nelson SE, Hanson SA (2001) Exposure to
soy-based formula in infancy and endocrinological and reproductive
outcomes in young adulthood. JAMA 286: 807–814
Su Y, Eason RR, Geng Y, Till SR, Badger TM, Simmen RC (2007a) In utero
exposure to maternal diets containing soy protein isolate, but not
genistein alone, protects young adult rat offspring from NMU-induced
mammary tumorigenesis. Carcinogenesis 28: 1046–1051
Su Y, Simmen FA, Xiao R, Simmen RC (2007b) Expression profiling of rat
mammary epithelial cells reveals candidate signaling pathways in dietary
protection from mammary tumors. Physiol Genomics 30: 8–16
Tang WY, Ho SM (2007) Epigenetic reprogramming and imprinting in
origins of disease. Rev Endocr Metab Disord 8: 173–182
Thomsen AR, Almstrup K, Nielsen JE, Sorensen IK, Petersen OW,
Leffers H, Breinholt VM (2006) Estrogenic effect of soy isoflavones on
mammary gland morphogenesis and gene expression profile. Toxicol Sci
93: 357–368
Thomsen AR, Mortensen A, Breinholt VM, Lindecrona RH, Penalvo JL,
Sorensen IK (2005) Influence of Prevastein, an isoflavone-rich soy
product, on mammary gland development and tumorigenesis in Tg.NK
(MMTV/c-neu) mice. Nutr Cancer 52: 176–188
Tominaga Y, Wang A, Wang RH, Wang X, Cao L, Deng CX (2007) Genistein
inhibits Brca1 mutant tumor growth through activation of DNA damage
checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death Differ
14: 472–479
Trichopoulos D, Lagiou P, Adami HO (2005) Towards an integrated model
for breast cancer etiology: the crucial role of the number of mammary
tissue-specific stem cells. Breast Cancer Res 7: 13–17
Trock BJ, Hilakivi-Clarke L, Clarke R (2006) Meta-analysis of soy intake
and breast cancer risk. J Natl Cancer Inst 98: 459–471
Turck D (2007) Soy protein for infant feeding: what do we know? Curr Opin
Clin Nutr Metab Care 10: 360–365
Vissac-Sabatier C, Coxam V, Dechelotte P, Picherit C, Horcajada MN,
Davicco MJ, Lebecque P, Bignon YJ, Bernard-Gallon D (2003)
Phytoestrogen-rich diets modulate expression of Brca1 and Brca2 tumor
suppressor genes in mammary glands of female Wistar rats. Cancer Res
63: 6607–6612
Wagner KU, Smith GH (2005) Pregnancy and stem cell behavior.
J Mammary Gland Biol Neoplasia 10: 25–36
Warri AM, Saarinen NM, Makela SI (2007) Can modulation of mammary
gland development by dietary factors support breast cancer prevention?
Horm Res 68: 248–260
Woodward WA, Chen MS, Behbod F, Rosen JM (2005) On mammary stem
cells. J Cell Sci 118: 3585–3594
Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC (2002) Adolescent
and adult soy intake and risk of breast cancer in Asian-Americans.
Carcinogenesis 23: 1491–1496
Wu AH, Yu MC, Tseng CC, Pike MC (2008) Epidemiology of soy exposures
and breast cancer risk. Br J Cancer 98: 9–14
Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N,
Chatterton RT, Liu B, Wang Q, Kim A, Murthy S, Thor AD (2003)
Hormonal and dietary modulation of mammary carcinogenesis in
mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 63:
2425–2433
Early life genistein exposures in modifying breast cancer risk
A Warri et al
1493
British Journal of Cancer (2008) 98(9), 1485–1493 & 2008 Cancer Research UK